(VIANEWS) – LeMaitre Vascular (LMAT), Neurocrine Biosciences (NBIX), BlackRock Capital Investment Corporation (BKCC) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. LeMaitre Vascular (LMAT)
22.6% sales growth and 9.31% return on equity
LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system. The company also provides carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; powered phlebectomy devices to remove varicose veins; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, it offers remote endarterectomy devices to remove plaque from arteries in the leg; valvulotomes, which cut valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, the company provides vascular patches, which are used for closure of vessels after surgical intervention; closure systems to attach vessels to one another with titanium clips instead of sutures; and surgical glue. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
Earnings Per Share
As for profitability, LeMaitre Vascular has a trailing twelve months EPS of $1.13.
PE Ratio
LeMaitre Vascular has a trailing twelve months price to earnings ratio of 42.42. Meaning, the purchaser of the share is investing $42.42 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.31%.
Volume
Today’s last reported volume for LeMaitre Vascular is 103717 which is 11.41% below its average volume of 117087.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Aug 15, 2023, the estimated forward annual dividend rate is 0.56 and the estimated forward annual dividend yield is 1.2%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
LeMaitre Vascular’s EBITDA is 148.81.
2. Neurocrine Biosciences (NBIX)
21% sales growth and 10.77% return on equity
Neurocrine Biosciences, Inc., a neuroscience-focused biopharmaceutical company, discovers, develops, and delivers various treatments for people with neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products also include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; NBI-827104 to treat rare pediatric epilepsy and other indications; and crinecerfont. The company's products in clinical development also comprise NBI-1065844 for the treatment of negative symptoms of schizophrenia; NBI-1065845 for the treatment of resistant depression; and NBI-1065846 for treating anhedonia in depression. It has license and collaboration agreements with Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; AbbVie Inc.; and Sentia Medical Sciences Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, Neurocrine Biosciences has a trailing twelve months EPS of $1.79.
PE Ratio
Neurocrine Biosciences has a trailing twelve months price to earnings ratio of 63.69. Meaning, the purchaser of the share is investing $63.69 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.77%.
Yearly Top and Bottom Value
Neurocrine Biosciences’s stock is valued at $114.01 at 16:22 EST, way under its 52-week high of $129.29 and way higher than its 52-week low of $89.04.
Volume
Today’s last reported volume for Neurocrine Biosciences is 436427 which is 38.31% below its average volume of 707504.
Moving Average
Neurocrine Biosciences’s value is higher than its 50-day moving average of $110.15 and way above its 200-day moving average of $103.12.
Previous days news about Neurocrine Biosciences(NBIX)
- According to Zacks on Monday, 16 October, "In the past 60 days, estimates per share for Neurocrine Biosciences 2023 have risen from $2.17 to $2.19. ", "Earnings of Neurocrine Biosciences beat estimates in one of the last four quarters and missed the same on the other three occasions. "
- According to Zacks on Tuesday, 17 October, "Earnings of Neurocrine Biosciences beat estimates in one of the last four quarters and missed the same on the other three occasions. "
- According to Zacks on Tuesday, 17 October, "In the past 60 days, estimates per share for Neurocrine Biosciences 2023 have risen from $2.17 to $2.19. ", "Earnings of Neurocrine Biosciences beat estimates in one of the last four quarters and missed the same on the other three occasions. "
3. BlackRock Capital Investment Corporation (BKCC)
17.5% sales growth and 3.24% return on equity
BlackRock Capital Investment Corporation, formerly known as BlackRock Kelso Capital Corporation, is a Business Development Company specializing in investments in middle market companies. The fund invests in all industries. It prefers to invest between $10 million and $50 million and can invest more or less in companies with EBITDA or operating cash flow between $10 million and $50 million. The fund invests in the form of senior and junior secured, unsecured, and subordinated debt securities and loans including cash flow, asset backed, and junior lien facilities and equity securities. It's equity investments can be structured in the form of warrants, preferred stock, common equity co-investments, and direct investments in common stock. The fund's debt investments are principally structured to provide for current cash interest and to a lesser extent non-cash interest, particularly with subordinated debt investments, through a pay-in-kind (PIK) feature. It can also make non-control investments.
Earnings Per Share
As for profitability, BlackRock Capital Investment Corporation has a trailing twelve months EPS of $0.15.
PE Ratio
BlackRock Capital Investment Corporation has a trailing twelve months price to earnings ratio of 22.67. Meaning, the purchaser of the share is investing $22.67 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.24%.
Sales Growth
BlackRock Capital Investment Corporation’s sales growth is 23.4% for the present quarter and 17.5% for the next.
Volume
Today’s last reported volume for BlackRock Capital Investment Corporation is 154914 which is 32.82% below its average volume of 230610.
Yearly Top and Bottom Value
BlackRock Capital Investment Corporation’s stock is valued at $3.40 at 16:22 EST, way below its 52-week high of $3.95 and way above its 52-week low of $3.03.
4. Fidus Investment Corporation (FDUS)
14.5% sales growth and 8.8% return on equity
Fidus Investment Corporation is a business development company. It specializing in leveraged buyouts, refinancings, change of ownership transactions, recapitalizations, strategic acquisitions, mezzanine, growth capital, business expansion, lower middle market investments, debt investments, subordinated and second lien loans, senior secured and unitranche debt, preferred equity, warrants, subordinated debt, senior subordinated notes, junior secured loans, and unitranche loans. It does not invest in turnarounds or distressed situations. The fund prefers to invest in aerospace and defense, business services, consumer products and services including retail, food, and beverage, healthcare products and services, industrial products and services, information technology services, niche manufacturing, transportation and logistics, and value-added distribution sectors. It seeks to invest in companies based in United States. The fund typically invests between $5 million and $15 million per transaction in companies with annual revenues between $10 million and $150 million and an annual EBITDA between $3 million and $20 million, but it can occasionally invest in larger or smaller companies. It seeks to acquire minority equity stakes and board observation rights in conjunction with its investments.
Earnings Per Share
As for profitability, Fidus Investment Corporation has a trailing twelve months EPS of $1.72.
PE Ratio
Fidus Investment Corporation has a trailing twelve months price to earnings ratio of 10.62. Meaning, the purchaser of the share is investing $10.62 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.8%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 44.5%, now sitting on 112.08M for the twelve trailing months.
Sales Growth
Fidus Investment Corporation’s sales growth is 24.3% for the present quarter and 14.5% for the next.
5. America Movil (AMX)
8.4% sales growth and 23.01% return on equity
América Móvil, S.A.B. de C.V. provides telecommunications services in Latin America and internationally. The company offers wireless and fixed voice services, including airtime, local, domestic, and international long-distance services; and network interconnection services. It also provides data services, such as data centers, data administration, and hosting services to residential and corporate clients; value-added services, including Internet access, messaging and other wireless entertainment, and corporate services; data transmission, email services, instant messaging, content streaming, and interactive applications; and wireless security services, mobile payment solutions, machine-to-machine services, mobile banking, virtual private network services, and video calls and personal communications services. In addition, the company offers residential broadband services; IT solutions to small businesses and large corporations; and cable and satellite television subscriptions. Further, it sells equipment, accessories, and computers; and offers telephone directories, wireless security, call center, advertising, media, and software development services. Additionally, the company provides video, audio, and other media content through the Internet directly from the content provider to the end user. It sells its products and services under the Telcel, Telmex Infinitum, and A1 brands through a network of retailers and service centers to retail customers; and through sales force to corporate customers. América Móvil, S.A.B. de C.V. was incorporated in 2000 and is based in Mexico City, Mexico.
Earnings Per Share
As for profitability, America Movil has a trailing twelve months EPS of $1.67.
PE Ratio
America Movil has a trailing twelve months price to earnings ratio of 9.76. Meaning, the purchaser of the share is investing $9.76 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.01%.
Moving Average
America Movil’s value is way under its 50-day moving average of $18.29 and way below its 200-day moving average of $20.36.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Jul 12, 2023, the estimated forward annual dividend rate is 0.71 and the estimated forward annual dividend yield is 4.25%.
6. Cigna (CI)
6.1% sales growth and 14.82% return on equity
The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers. The company's Cigna Healthcare segment offers medical, pharmacy, behavioral health, dental, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as individual health insurance plans; and health care coverage in its international markets, as well as health care benefits for mobile individuals and employees of multinational organizations. The company also offers permanent insurance contracts sold to corporations to provide coverage on the lives of certain employees for financing employer-paid future benefit obligations. It distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was formerly known as Cigna Corporation and changed its name to The Cigna Group in February 2023. The Cigna Group was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Earnings Per Share
As for profitability, Cigna has a trailing twelve months EPS of $21.84.
PE Ratio
Cigna has a trailing twelve months price to earnings ratio of 14.4. Meaning, the purchaser of the share is investing $14.4 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.82%.
Moving Average
Cigna’s worth is way higher than its 50-day moving average of $285.77 and way above its 200-day moving average of $280.39.
Revenue Growth
Year-on-year quarterly revenue growth grew by 7.1%, now sitting on 186.02B for the twelve trailing months.
Previous days news about Cigna(CI)
- Why cigna (ci) dipped more than broader market today. According to Zacks on Tuesday, 17 October, "In terms of valuation, Cigna is currently trading at a Forward P/E ratio of 12.58. ", "For comparison, its industry has an average Forward P/E of 17.11, which means Cigna is trading at a discount to the group."
7. First Community Bankshares (FCBC)
5.9% sales growth and 10.37% return on equity
First Community Bankshares, Inc. operates as the financial holding company for First Community Bank that provides various banking products and services. It offers demand deposit accounts, savings and money market accounts, certificates of deposit, and individual retirement arrangements; commercial, consumer, and real estate mortgage loans, as well as lines of credit; various credit and debit cards, and automated teller machine card services; and corporate and personal trust services. The company also provides wealth management services, including trust management, estate administration, and investment advisory services; and investment management services. It serves individuals and businesses across various industries, such as education, government, and health services; coal mining and gas extraction; retail trade; construction; manufacturing; tourism; and transportation. As of December 31, 2021, the company operated 49 branches, including 17 branches in West Virginia, 23 branches in Virginia, 7 branches in North Carolina, and 2 branches in Tennessee. First Community Bankshares, Inc. was founded in 1874 and is headquartered in Bluefield, Virginia.
Earnings Per Share
As for profitability, First Community Bankshares has a trailing twelve months EPS of $2.83.
PE Ratio
First Community Bankshares has a trailing twelve months price to earnings ratio of 10.72. Meaning, the purchaser of the share is investing $10.72 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.37%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is 17.9% and a drop 13% for the next.
Moving Average
First Community Bankshares’s worth is under its 50-day moving average of $31.05 and above its 200-day moving average of $29.64.
